Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed six months of maintenance treatment in the SP513 double-blind trial~Exclusion Criteria:~* Subjects who had an ongoing serious adverse event from SP513 double-blind trial that was assessed as related to study medication

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine

Based on this trial design, predict the completion outcome and termination type (if applicable).